Cargando…

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis

BACKGROUND: Significant progress has been made in the investigation of neoadjuvant immune-chemoradiotherapy (NICRT) and neoadjuvant immune-chemotherapy (NICT) on the outcomes of esophageal cancer patients. To summarize the current developments, a systematic review and meta-analysis were conducted to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yunsong, Bao, Yongxing, Yang, Xu, Sun, Shuang, Yuan, Meng, Ma, Zeliang, Zhang, Wanting, Zhai, Yirui, Wang, Yang, Men, Yu, Qin, Jianjun, Xue, Liyan, Wang, Jun, Hui, Zhouguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902949/ https://www.ncbi.nlm.nih.gov/pubmed/36761760 http://dx.doi.org/10.3389/fimmu.2023.1117448

Ejemplares similares

Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta‐analysis
por: Bao, Yongxing, et al.
Publicado: (2022)

Endostar (rh‐endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Yuan, Meng, et al.
Publicado: (2021)

Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis
por: Ma, Zeliang, et al.
Publicado: (2021)

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Famitinib enhances the antitumor effect of radioimmunotherapy in murine lung cancer
por: Yuan, Meng, et al.
Publicado: (2022)

The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients
por: Yuan, Meng, et al.
Publicado: (2021)

Enhanced prediction of postoperative radiotherapy‐induced esophagitis in non‐small cell lung cancer: Dosiomic model development in a real‐world cohort and validation in the PORT‐C randomized controlled trial
por: Ma, Zeliang, et al.
Publicado: (2023)

Higher Lung and Heart Doses Decrease Early and Long-Term Survival, Respectively, in Patients With Non-Small Cell Lung Cancer Undergoing Postoperative Radiation
por: Ma, Zeliang, et al.
Publicado: (2023)

Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study
por: Yang, Xu, et al.
Publicado: (2021)

Reply: Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Bao, Yongxing, et al.
Publicado: (2022)

Postoperative radiotherapy improves survival of patients with ypN2 non‐small cell lung cancer after neoadjuvant chemotherapy followed by surgery – A propensity score matching study of the Surveillance, Epidemiology, and End Results database
por: Bao, Yongxing, et al.
Publicado: (2021)

Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer
por: Zhang, Baihua, et al.
Publicado: (2023)

Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis
por: Wang, He, et al.
Publicado: (2022)

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching
por: Jing, Shao-Wu, et al.
Publicado: (2022)

Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study
por: He, Wenwu, et al.
Publicado: (2022)

Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Xu, Lei, et al.
Publicado: (2022)

Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2018)

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
por: Wang, Yaqi, et al.
Publicado: (2022)

Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma
por: Chen, Yongshun, et al.
Publicado: (2022)

Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer
por: Lin, Guang-Tan, et al.
Publicado: (2022)

Risk of cardiac‐related mortality in stage IIIA‐N2 non‐small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database
por: Sun, Xin, et al.
Publicado: (2021)

Comparison of Neoadjuvant Immunotherapy Plus Chemotherapy versus Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study
por: Zhao, Junfeng, et al.
Publicado: (2023)

Perioperative outcomes of neoadjuvant immunotherapy plus chemotherapy and neoadjuvant chemoradiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective comparative cohort study
por: Zhang, Hai, et al.
Publicado: (2023)

Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy
por: Gao, Lin-Rui, et al.
Publicado: (2022)

High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis
por: Sun, Xin, et al.
Publicado: (2020)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis
por: Wang, Hesong, et al.
Publicado: (2023)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015)

Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
por: Kang, Jingjing, et al.
Publicado: (2018)

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
por: Qin, Hao, et al.
Publicado: (2023)

Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma
por: Arbore, Giuseppina, et al.
Publicado: (2023)

Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis
por: Fan, Ningbo, et al.
Publicado: (2021)

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
por: Xu, Hao, et al.
Publicado: (2023)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
por: Duan, Hongtao, et al.
Publicado: (2022)

The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
por: Lv, Huilai, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
por: Zhu, Jie, et al.
Publicado: (2022)

Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis
por: Guo, Yaru, et al.
Publicado: (2022)

Impact of Radiation Dose on Survival for Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemoradiotherapy
por: Yang, Yang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vamp2ac69gvejmrbgemn1k8os2